New Diabetes Drug Alert: Rybelsus (semaglutide)
On September 20, 2019, the FDA approved Rybelsus® (semaglutide) oral tablets to improve glycemic control in adults with Type II diabetes. Please read below for more information regarding this new drug, including important dosing information and its place in therapy (click to zoom in):
If you have any questions or concerns regarding GDMT for diabetes or would like resources for your practice (ex: GLP-1 agonist comparison chart), please feel free to contact the SVHP Pharmacist for additional resources. We hope to continue providing safe and excellent quality care for our mutual patients.
1. Rybelsus® Prescribing Information. Novo Nordisk. https://www.novo-pi.com/rybelsus.pdf. Accessed November 2019.
2. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. https://doi.org/10.1056/NEJMoa1901118. doi: 10.1056/NEJMoa1901118.
3. Gardner, J. Novo gains approval for first oral diabetes drug of its kind. https://www.biopharmadive.com/news/novo-oral-diabetes-drug-approval-Rybelsus-semaglutide/563416/ Accessed November 2019.
(c) 2019, SVHP. This document contains proprietary and confidential information and shall not be used, disclosed, or reproduced, in whole or in part, without the prior written consent of St. Vincent’s Health Partners, Inc. The contents of this document are provided on an “as is” basis. Nothing in this publication is intended as medical advice and it should not be taken to replace, subvert, or otherwise modify medical advice from, or the clinical judgement of, a qualified medical practitioner. This publication was made with contributions from Kaitlyn McCarthy, PharmD.